Reactivation kinetics of HIV-1 and susceptibility of reactivated latently infected CD4+ T cells to HIV-1-specific CD8+ T cells

Journal of Virology

Volumn 89, Issue 18, 2015, Pages 9631-9638

  Walker Sperling, Victoria E K ^a   Cohen, Valerie J ^a   Tarwater, Patrick M ^b   Blankson, Joel N ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Paul L Foster School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA;

ARTICLE; BLOOD SAMPLING; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ISOLATION; CONTROLLED STUDY; EX VIVO STUDY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RNA ISOLATION; UPREGULATION; VIRUS REACTIVATION; VIRUS RELEASE; VIRUS TRANSCRIPTION; BIOLOGICAL MODEL; CLINICAL TRIAL; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MALE; PATHOLOGY; PHYSIOLOGY; VIRUS ACTIVATION; VIRUS LATENCY;

CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MODELS, IMMUNOLOGICAL; VIRUS ACTIVATION; VIRUS LATENCY; VIRUS RELEASE;

EID: 84940570919     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01454-15     Document Type: Article

References (43)

1. Siliciano JD, Siliciano RF. 2013. HIV-1 eradication strategies: design and assessment. Curr Opin HIV AIDS 8:318-325. http://dx.doi.org/10.1097/COH.0b013e328361eaca.
2. Archin NM, Margolis DM. 2014. Emerging strategies to deplete the HIV reservoir. Curr Opin Infect Dis 27:29-35. http://dx.doi.org/10.1097/QCO.0000000000000026.
3. Henrich TJ, Hanhauser E, Marty FM, Sirignano MN, Keating S, Lee TH, Robles YP, Davis BT, Li JZ, Heisey A, Hill AL, Busch MP, Armand P, Soiffer RJ, Altfeld M, Kuritzkes DR. 2014. Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases. Ann Intern Med 161:319-327. http://dx.doi.org/10.7326/M14-1027.
4. Luzuriaga K, Gay H, Ziemniak C, Sanborn KB, Somasundaran M, Rainwater-Lovett K, Mellors JW, Rosenbloom D, Persaud D. 2015. Viremic relapse after HIV-1 remission in a perinatally infected child. N Engl J Med 372:786-788. http://dx.doi.org/10.1056/NEJMc1413931.
5. Butler KM, Gavin P, Coughlan S, Rochford A, Donagh SM, Cunningham O, Poulsom H, Watters SA, Klein N. 2015. Rapid viral rebound after 4 years of suppressive therapy in a seronegative HIV-1 infected infant treated from birth. Pediatr Infect Dis J 34:e48-e51. http://dx.doi.org/10.1097/INF.0000000000000570.
6. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. 1995. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373:123-126. http://dx.doi.org/10.1038/373123a0.
7. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. 1996. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271:1582-1586. http://dx.doi.org/10.1126/science.271.5255.1582.
8. Markowitz M, Louie M, Hurley A, Sun E, Di Mascio M, Perelson AS, Ho DD. 2003. A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo. J Virol 77:5037-5038. http://dx.doi.org/10.1128/JVI.77.8.5037-5038.2003.
9. Dixit NM, Markowitz M, Ho DD, Perelson AS. 2004. Estimates of intracellular delay and average drug efficacy from viral load data of HIVinfected individuals under antiretroviral therapy. Antivir Ther 9:237-246.
10. Folks T, Powell DM, Lightfoote MM, Benn S, Martin MA, Fauci AS. 1986. Induction of HTLV-3rd/LAV from a nonvirus-producing T-cell line: implications for latency. Science 231:600-602. http://dx.doi.org/10.1126/science.3003906.
11. Nabel G, Baltimore D. 1987. An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature 326:711- 713. http://dx.doi.org/10.1038/326711a0.
12. Kinoshita S, Chen BK, Kaneshima H, Nolan GP. 1998. Host control of HIV-1 parasitism in T cells by the nuclear factor of activated T cells. Cell 95:595-604. http://dx.doi.org/10.1016/S0092-8674(00)81630-X.
13. Colin L, Van Lint C. 2009. Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies. Retrovirology 6:111. http://dx.doi.org/10.1186/1742-4690-6-111.
14. Zhu Y, Pe'ery T, Peng J, Ramanathan Y, Marshall N, Marshall T, Amendt B, Mathews MB, Price DH. 1997. Transcription elongation factor P-TEFb is required for HIV-1 tat transactivation in vitro. Genes Dev 11:2622-2632. http://dx.doi.org/10.1101/gad.11.20.2622.
15. Kim SY, Byrn R, Groopman J, Baltimore D. 1989. Temporal aspects of DNA and RNA synthesis during human immunodeficiency virus infection: evidence for differential gene expression. J Virol 63:3708-3713.
16. Schwartz O, Maréchal V, Le Gall S, Lemonnier F, Heard JM. 1996. Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein. Nat Med 2:338-342. http://dx.doi.org/10.1038/nm0396-338.
17. Collins KL, Chen BK, Kalams SA, Walker BD, Baltimore D. 1998. HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes. Nature 391:397- 401. http://dx.doi.org/10.1038/34929.
18. + T-cell cytolytic activity and cytokine production. J Virol 76:7535-7543. http://dx.doi.org/10.1128/JVI.76.15.7535-7543.2002.
19. Yang OO, Nguyen PT, Kalams SA, Dorfman T, Göttlinger HG, Stewart S, Chen IS, Threlkeld S, Walker BD. 2002. Nef-mediated resistance of human immunodeficiency virus type 1 to antiviral cytotoxic T lymphocytes. J Virol 76:1626 -1631. http://dx.doi.org/10.1128/JVI.76.4.1626-1631.2002.
20. Bullen CK, Laird GM, Durand CM, Siliciano JD, Siliciano RF. 2014. New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. Nat Med 20:425-429. http://dx.doi.org/10.1038/nm.3489.
21. Laird GM, Bullen CK, Rosenbloom DI, Martin AR, Hill AL, Durand CM, Siliciano JD, Siliciano RF. 2015. Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations. J Clin Invest 125:1901-1912. http://dx.doi.org/10.1172/JCI80142.
22. Ho YC, Shan L, Hosmane NN, Wang J, Laskey SB, Rosenbloom DI, Lai J, Blankson JN, Siliciano JD, Siliciano RF. 2013. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell 155:540-551. http://dx.doi.org/10.1016/j.cell.2013.09.020.
23. Weinberger LS, Burnett JC, Toettcher JE, Arkin AP, Schaffer DV. 2005. Stochastic gene expression in a lentiviral positive-feedback loop: HIV-1 Tat fluctuations drive phenotypic diversity. Cell 122:169-182. http://dx.doi.org/10.1016/j.cell.2005.06.006.
24. + T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat Immunol 3:1061-1068. http://dx.doi.org/10.1038/ni845.
25. + T cells. Blood 107:4781-4789. http://dx.doi.org/10.1182/blood-2005-12-4818.
26. Sáez-Cirión A, Lacabaratz C, Lambotte O, Versmisse P, Urrutia A, Boufassa F, Barré-Sinoussi F, Delfraissy JF, Sinet M, Pancino G, Venet A, Agence Nationale de Recherches sur le Sida EP36 HIV Controllers Study Group. 2007. HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc Natl Acad Sci U S A 104:6776-6781. http://dx.doi.org/10.1073/pnas.0611244104.
27. + T cells is required for HIV-infected cell elimination associated with immune control. Immunity 29:1009- 1021. http://dx.doi.org/10.1016/j.immuni.2008.10.010.
28. Hersperger AR, Pereyra F, Nason M, Demers K, Sheth P, Shin LY, Kovacs CM, Rodriguez B, Sieg SF, Teixeira-Johnson L, Gudonis D, Goepfert PA, Lederman MM, Frank I, Makedonas G, Kaul R, Walker BD, Betts MR. 2010. Perforin expression directly ex vivo by HIV-specific CD8 T-cells is a correlate of HIV elite control. PLoS Pathog 6:e1000917. http://dx.doi.org/10.1371/journal.ppat.1000917.
29. + T cells. Retrovirology 10:68. http://dx.doi.org/10.1186/1742-4690-10-68.
30. Blankson JN, Bailey JR, Thayil S, Yang HC, Lassen K, Lai J, Gandhi SK, Siliciano JD, Williams TM, Siliciano RF. 2007. Isolation and characterization of replication-competent human immunodeficiency virus type 1 from a subset of elite suppressors. J Virol 81:2508-2518. http://dx.doi.org/10.1128/JVI.02165-06.
31. +T cells, abstr 427. Abstr Conf Retroviruses Opportun Infect 2015. International Antiviral Society-USA/CROI Foundation, San Francisco, CA.
32. + T cell depletion in humanized BLT mice. J Virol 88:3340-3352. http://dx.doi.org/10.1128/JVI.03380-13.
33. Pereyra F, Addo MM, Kaufmann DE, Liu Y, Miura T, Rathod A, Baker B, Trocha A, Rosenberg R, Mackey E, Ueda P, Lu Z, Cohen D, Wrin T, Petropoulos CJ, Rosenberg ES, Walker BD. 2008. Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J Infect Dis 197:563-571. http://dx.doi.org/10.1086/526786.
34. Stafford MA, Corey L, Cao Y, Daar ES, Ho DD, Perelson AS. 2000. Modeling plasma virus concentration during primary HIV infection. J Theor Biol 203:285-301. http://dx.doi.org/10.1006/jtbi.2000.1076.
35. Little SJ, McLean AR, Spina CA, Richman DD, Havlir DV. 1999. Viral dynamics of acute HIV-1 infection. J Exp Med 190:841-850. http://dx.doi.org/10.1084/jem.190.6.841.
36. + T cells in peripheral blood after initiation of highly active antiretroviral therapy. J Virol 75:6508- 6516. http://dx.doi.org/10.1128/JVI.75.14.6508-6516.2001.
37. + T-cell polyfunctionality, proliferation, and cytotoxicity are not restored by antiretroviral therapy. J Virol 83: 11876-11889. http://dx.doi.org/10.1128/JVI.01153-09.
38. Shan L, Deng K, Shroff NS, Durand CM, Rabi SA, Yang HC, Zhang H, Margolick JB, Blankson JN, Siliciano RF. 2012. Stimulation of HIV-1- specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 36:491-501. http://dx.doi.org/10.1016/j.immuni.2012.01.014.
39. Sung JA, Lam S, Garrido C, Archin N, Rooney CM, Bollard CM, Margolis DM. 2015. Expanded cytotoxic T-cell lymphocytes target the latent HIV reservoir. J Infect Dis 212:258-263. http://dx.doi.org/10.1093/infdis/jiv022.
40. Jones RB, O'Connor R, Mueller S, Foley M, Szeto GL, Karel D, Lichterfeld M, Kovacs C, Ostrowski MA, Trocha A, Irvine DJ, Walker BD. 2014. Histone deacetylase inhibitors impair the elimination of HIVinfected cells by cytotoxic T-lymphocytes. PLoS Pathog 10:e1004287. http://dx.doi.org/10.1371/journal.ppat.1004287.
41. + T cells, abstr 390 Abstr Conf Retroviruses Opportun Infect 2015. International Antiviral Society-USA/CROI Foundation, San Francisco, CA.
42. + T cells in HIV-1- infected elite suppressors. J Virol 86:13679 -13688. http://dx.doi.org/10.1128/JVI.02439-12.
43. Hansen SG, Piatak M, Jr, Ventura AB, Hughes CM, Gilbride RM, Ford JC, Oswald K, Shoemaker R, Li Y, Lewis MS, Gilliam AN, Xu G, Whizin N, Burwitz BJ, Planer SL, Turner JM, Legasse AW, Axthelm MK, Nelson JA, Früh K, Sacha JB, Estes JD, Keele BF, Edlefsen PT, Lifson JD, Picker LJ. 2013. Immune clearance of highly pathogenic SIV infection. Nature 502:100-104.